GSK3532795 is an orally active inhibitor of HIV-1 maturation. GSK3532795 combines broad coverage of polymorphic viruses (EC50: 15 nM toward a panel of common polymorphisms representative of 96.5% HIV-1 subtype B virus) with a favorable pharmacokinetic pro
GSK-3532795 is a second generation inhibitor of hiv-1 maturation, exhibiting a broader spectrum of antiviral effect in vitro and in clinical studies than the prototypical maturation inhibitor bevirimat